Ruxolitinib (Opzelura)

Canada’s Drug Agency (CDA-AMC) recommends that Opzelura be reimbursed by public drug plans for the topical treatment of moderate atopic dermatitis (AD) in adults aged 18 years and older who have had an inadequate response to, are intolerant of, or have a contraindication to topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), if certain conditions are met. The Canadian Drug Expert Committee (CDEC) determined that Opzelura demonstrates acceptable clinical value for adults with moderate AD who have had an inadequate response to, cannot tolerate, or cannot use TCS and TCI. Opzelura is expected to provide an additional topical treatment option before patients move on to systemic treatments. Therefore, acceptable clinical value refers to added value compared with vehicle cream. Evidence from the TRuE-AD4 clinical trial showed that Opzelura improved the severity and extent of AD, itch, and quality of life compared with vehicle cream. Opzelura may also provide a nonsteroidal topical treatment option for patients whose disease can still be managed with topical therapy before moving to systemic treatment. There is more uncertainty about how Opzelura compares with treatments that patients would otherwise receive in clinical practice in Canada. Vehicle cream is not an active treatment, and there were no direct trials comparing Opzelura with phototherapy, conventional systemic immunosuppressants, biologic drugs, or oral Janus kinase inhibitors. Indirect evidence comparing Opzelura with selected systemic treatments was also uncertain and did not establish whether Opzelura provides more, less, or similar benefit compared with these treatments. Despite this uncertainty, CDEC concluded that the benefits of Opzelura compared with vehicle cream, together with its short-term safety profile and potential to provide another nonsteroidal topical treatment option before systemic therapy, were sufficient to support reimbursement. CDA-AMC previously reviewed Opzelura for the topical treatment of mild to moderate AD in patients aged 12 years and older and issued a recommendation not to reimburse in May 2025. This resubmission focuses on a narrower patient population and includes new evidence from the TRuE-AD4 clinical trial in adults with moderate AD who have had an inadequate response to, are intolerant of, or cannot use TCS and TCI. The resubmission also includes updated indirect evidence comparing Opzelura with selected systemic treatments.